APA (7th ed.) Citation

Herviou, L., Kassambara, A., Boireau, S., Robert, N., Requirand, G., Müller-Tidow, C., . . . Moreaux, J. (2018). PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clinical epigenetics, 10, . https://doi.org/10.1186/s13148-018-0554-4

Chicago Style (17th ed.) Citation

Herviou, Laurie, et al. "PRC2 Targeting Is a Therapeutic Strategy for EZ Score Defined High-risk Multiple Myeloma Patients and Overcome Resistance to IMiDs." Clinical Epigenetics 10 (2018). https://doi.org/10.1186/s13148-018-0554-4.

MLA (9th ed.) Citation

Herviou, Laurie, et al. "PRC2 Targeting Is a Therapeutic Strategy for EZ Score Defined High-risk Multiple Myeloma Patients and Overcome Resistance to IMiDs." Clinical Epigenetics, vol. 10, 2018, https://doi.org/10.1186/s13148-018-0554-4.